Wall Street analysts expect that Zafgen Inc (NASDAQ:ZFGN) will post earnings of ($0.59) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Zafgen’s earnings. Zafgen posted earnings per share of ($0.38) in the same quarter last year, which would indicate a negative year-over-year growth rate of 55.3%. The business is scheduled to issue its next quarterly earnings report after the market closes on Tuesday, March 6th.
According to Zacks, analysts expect that Zafgen will report full-year earnings of ($2.02) per share for the current financial year. For the next financial year, analysts forecast that the company will post earnings of ($1.35) per share. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Zafgen.
A number of brokerages have recently commented on ZFGN. Zacks Investment Research downgraded Zafgen from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $6.63.
Shares of Zafgen (ZFGN) opened at $8.26 on Wednesday. The company has a market capitalization of $225.96, a price-to-earnings ratio of -4.59 and a beta of -0.65. Zafgen has a 1 year low of $3.21 and a 1 year high of $9.36.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.